Molecule News and Research

RSS

ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.

24 Feb 2011

Scientists complete protein 3D structural sequence essential for cellular function

Researchers at IRB Barcelona have completed the 3D structural sequence adopted by several essential proteins in the exchange of substances between the extra and intracellular milieu. This finding provides a global perspective of the structural changes that occur in these relevant proteins during basic cell processes, such as protein synthesis, the regulation of metabolism and cell volume, and nerve transmission.

24 Feb 2011

New vaccine offers hope against Hepatitis C

Immunology: Three percent of the world's population is currently infected by hepatitis C. The virus hides in the liver and can cause cirrhosis and liver cancer, and it's the most frequent cause of liver transplants in Denmark.

24 Feb 2011

Biological pathways in PTSD revealed: Study

Up to 20% of the population exposed to a horror of a war, trauma or abuse may go on to develop post-traumatic stress disorder. PTSD, as it is better known, is a debilitating psychiatric disorder marked by flashbacks and nightmares. Till date the biological basis for PTSD was unclear. But a new study offers clues about why some people rebound from horrific events while others relive them, and may lead to predictive tests and even treatments.

23 Feb 2011

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project “FLUCURE” supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germany, Bulgaria, Lithuania, and the Netherlands.

23 Feb 2011

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project "FLUCURE" supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses.

23 Feb 2011

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

A strategy developed by Massachusetts General Hospital (MGH) researchers to shield the ovaries of female mammals from the damaging effects of radiation and chemotherapy has passed an important milestone. A collaborative study with investigators from Oregon Health and Sciences University (OHSU), published online in the journal Fertility and Sterility, reports that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.

23 Feb 2011

New method integrates supercomputer simulation and experimental results

A theoretical technique developed at the Department of Energy's Oak Ridge National Laboratory is bringing supercomputer simulations and experimental results closer together by identifying common "fingerprints."

23 Feb 2011

Cerasome filled molecular-sized bubbles to target liver cancer cells

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

23 Feb 2011

New DNA technology to study cystic fibrosis 'superbug' during infection

The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. Scientists at Liverpool identified a particularly virulent strain of the bacteria that is transmissible between patients. The Liverpool Epidemic Strain (LES), referred to as a cystic fibrosis 'superbug', can cause aggressive infection and results in progressive lung decline.

23 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Harbor BioSciences, Inc., which is investigating the use the company's proprietary compound Triolex as a treatment for Parkinson's disease with funding from The Michael J. Fox Foundation, announced positive results in initial preclinical studies.

23 Feb 2011

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

A University of Missouri researcher believes there could be a new drug compound that could kill breast cancer cells. The compound might also help with controlling cholesterol.

23 Feb 2011

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.

22 Feb 2011

KemPharm commences KP201 Phase 1 trial for pain

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers with KP201, its novel abuse deterrent prodrug of hydrocodone for pain. KP201 is a new chemical entity and is the most advanced opioid-based lead candidate in KemPharm's emerging pipeline.

22 Feb 2011

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

A group of chemical compounds used by a species of tropical seaweed to ward off fungus attacks may have promising antimalarial properties for humans. The compounds are part of a unique chemical signaling system that seaweeds use to battle enemies - and that may provide a wealth of potential new pharmaceutical compounds.

22 Feb 2011

New method to help unravel structural mysteries of nature

The team of Professor Burkhard Luy from KIT and Junior Professor Stefan F. Kirsch from the TUM has now shown for the first time that certain NMR parameters, the so-called residual dipolar couplings, can make a significant contribution towards determining the constitution of chemical compounds when traditional methods fail.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

New study: Fast food meal consumption can affect inflammatory responses in blood vessels

The effect of a high-fat meal on blood vessel walls can vary among individuals depending on factors such as their waist size and triglyceride levels, suggests new research at UC Davis.

17 Feb 2011

FAK enzyme plays a key role in preparing lung tissue for metastatic development

A Massachusetts General Hospital study has identified a new role for an important enzyme in preparing lung tissue for the development of metastases.

17 Feb 2011

Molecule News and Research

ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

Scientists complete protein 3D structural sequence essential for cellular function

New vaccine offers hope against Hepatitis C

Biological pathways in PTSD revealed: Study

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

New method integrates supercomputer simulation and experimental results

Cerasome filled molecular-sized bubbles to target liver cancer cells

New DNA technology to study cystic fibrosis 'superbug' during infection

New nanoparticle can help develop vaccines against HIV, malaria

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

KemPharm commences KP201 Phase 1 trial for pain

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

New method to help unravel structural mysteries of nature

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

New study: Fast food meal consumption can affect inflammatory responses in blood vessels

FAK enzyme plays a key role in preparing lung tissue for metastatic development

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News